CIK 0001680581
- Non-accelerated filer
- Smaller reporting company
Fulcrum Therapeutics, Inc.
Sign in to watch- Ticker
- FULC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 474839948
- Phone
- +1 617-651-8851
- Business address
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-03-02 | Cadavid Diego SVP Clinical Development | Sale | −315 | $18.13 | $6K | 66,785 |
| 2020-02-24 | Thomson Peter G. VP Finance & Accounting | Sale | −2,648 | $16.18 | $43K | 30,923 |
| 2020-02-24 | Thomson Peter G. VP Finance & Accounting | Sale | −2,102 | $17.43 | $37K | 28,821 |
| 2020-02-24 | Thomson Peter G. VP Finance & Accounting | Sale | −250 | $18.61 | $5K | 28,571 |
| 2020-02-19 | Gould Robert J | Sale | −2,500 | $20.00 | $50K | 554,845 |
| 2020-02-19 | Wallace Owen B. Chief Scientific Officer | Exercise or conversion | +6,088 | $7.84 | $48K | 133,176 |
| 2020-02-19 | Wallace Owen B. Chief Scientific Officer | Sale | −6,088 | $20.00 | $122K | 127,088 |
| 2020-02-19 | Wallace Owen B. Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −6,088 | 88,126 | ||
| 2020-02-03 | Cadavid Diego SVP Clinical Development | Sale | −2,143 | $17.33 | $37K | 68,928 |
| 2020-01-23 | Stuart Bryan Chief Operating Officer | Grant or award · Stock Option (right to buy) | +105,000 | 105,000 | ||
| 2020-01-23 | Cadavid Diego SVP Clinical Development | Grant or award · Stock Option (right to buy) | +55,440 | 55,440 | ||
| 2020-01-23 | Thomson Peter G. VP Finance & Accounting | Sale | −4,738 | $17.17 | $81K | 33,833 |
| 2020-01-23 | Thomson Peter G. VP Finance & Accounting | Sale | −262 | $18.05 | $5K | 33,571 |
| 2020-01-23 | Thomson Peter G. VP Finance & Accounting | Grant or award · Stock Option (right to buy) | +33,100 | 33,100 | ||
| 2020-01-23 | Gould Robert J President & CEO | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2020-01-23 | Wallace Owen B. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +58,900 | 58,900 | ||
| 2020-01-02 | Dorton Katina Director | Grant or award · Stock Option (right to buy) | +18,571 | 18,571 | ||
| 2019-07-22 | GLAXOSMITHKLINE PLC 10% owner | Conversion | +1,785,714 | 1,785,714 | ||
| 2019-07-22 | GLAXOSMITHKLINE PLC 10% owner | Conversion · Series B Preferred Stock | −12,500,000 | 0 | ||
| 2019-07-22 | Sanofi 10% owner | Conversion | +464,285 | 464,285 |
Page 13 of 15 · 291 trades